Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Muck,
Looks some very good tests to tempt the retail market to save the time and stress of dealing with Dr's, esp on the big ones like Bowl and prostate cancer.
Perhaps just a little observation, but we know Salignostics have been progressing FDA approval for Salistick for nearly three years now, that they are currently "positioning" the product in the States, and that Salistick made Time Magazine's top 200 inventions of 2023.
Well today Time published its top 100 most influential people in Health and included Raluca Cohen, one of the scientist behind Salistick, in this list.
Can't hurt in the US positioning....
https://time.com/collection/time100-health/
https://time.com/6962679/raluca-cohen/
A little more here
https://neutrapharma.com/products/home-self-test-kits/
Interesting post from Neutrapharma today, introducing their “exclusive collaboration” with us to distribute our AST range.
To be honest I don’t think this agreement is new. What is a little more interesting is that they say 2 new tests will be launched this summer. Perhaps the FOFH STI tests?
https://www.linkedin.com/posts/neutrapharma-europe-limited_exclusive-pharmacy-pharmacist-activity-7191728649132204033-_xu5?utm_source=share&utm_medium=member_desktop
Looks like Loop are in the middle of another funding round, seeking £5m with 15% intended for U.K. launch. Some interesting info in this pitch slide.
https://www.linkedin.com/posts/choskin-exec-leader_techtuesday-innovation-investor-activity-7191028516694466561-l55L?utm_source=share&utm_medium=member_desktop
It would be more of a liability in my opinion. Far too much risk involved. Not much point in speculation around acquisitions, ABDX's business/growth model looks just fine as it is for now.
I really hope not. Growing through acquisition always sounds great but the reality in my experience is that integration frictions and costs are underestimated. And I agree, it’s unlikely we could afford it anyway.
I have though about this too KOL, but I don't think they could afford it right now. Plus there would be some duplication of production I think.
It depends on how desperate AVCT would be to unload it but even so its hard to think it would be less then £10m.
I guess it could only work if the assets were substantially higher than the cost of purchase. But even then ABDX are so close to proving financial sustainability I can't see the need to give the market a reason to hold back with a "risky" aquistition
Still, you never know.
Would Abingdon consider looking at acquiring Avacta Dx unit that looks like this might be up for sale?
When are they ever correct ? Seriously they never are
Thanks Muck for the info as ever. Good to hear about the Vitamin D stock. Shame the Boots deal isn't as exciting as was first thought. Don't forget though, if analysts raise price targets, they are looking at the entire growth projection which must surely be building quite rapidly. Still looking good IMO
I’m afraid to say the Boots tie up might not be as lucrative as I’d thought.
If you look through this Amazon listing for the AST Vit D test you will see it originates from China and is made by ( Hangzhou) AllTest. That is the same manufacturer for all other AST tests listed on Amazon, as well as being the manufacturer for all MHC lateral flow tests.
So if you buy a Boots, AST, or MHC lateral flow test, I think the reality is it will be precisely the same test in the box, ie a Chinese AllTest.
That perhaps explains the involvement of Crest Medical. I suspect we are an authorised AllTest distributor with rights to brand, that Crest are a Boots supplier, that Crest have sourced the tests from us for supply to Boots, and that we have assisted in their re-branding. That would tie up much more with what Yates said in the investor presentation.
We will still of course be getting a cut from all “Boots” tests sold, just not as much as I’d thought. The bigger value lies in having created the relationship such that future tests we may make, like the FOFH tests, could find their way onto Boots shelves.
Others may well have twigged this long before I have, I just assumed we made the AST tests - feel a bit of an idiot to be honest.
https://www.amazon.co.uk/Abingdon-Simply-Test-Vitamin-Test/dp/B0BXM3QTRD?ref_=ast_sto_dp
Another little one…
Whatever own brand Vitamin D stock Boots bought has sold out online. “New stock coming soon”. We don’t know, of course, how much they bought initially, but it’s still a good sign I think.
If Chris hand will is maybe looking for a capital exit but at what price would tempt him ?
Just a bit of a throw away observation, but I did notice in the FOFH RNS that ABDX highlighted they will have rights to offer the STI tests as own brand retailer products, and you have to wonder if they have Boots in mind. Whatever the case, its clear that retailer own branding is something ABDX are pursuing and, of course, we can offer exactly the same test ( I think) to multiple retailers as an own brand product.
Lol, so glad I'm on your team, Muck. I'm going to make a pretty decent profit here because I now think I know all there is to know about this investment. You're a God-send. Have a great day!
In that vein, and to give a flavour, BBI were sold in 2021 for £400m.
Should be remembered that they provide antibodies, antigens, labels, and complementary reagents, as well as do everything ABDX does. But still…..
https://www.prnewswire.com/news-releases/novo-holdings-acquires-bbi-group-301312183.html#:~:text=COPENHAGEN%2C%20Denmark%2C%20June%2015%2C,value%20of%20over%20GBP%20400
Well said, and in fewer words than I normally manage! Maybe I should try the wine.
Longer term, well more medium term I think, I expect that Chris Hand will be looking for a capital exit. He’s already built, AIM listed and then sold one drugs of abuse LFT diagnostics company (Cozart, now part of Abbot) for £65m, and he must be looking at ABDX as his juicy retirement fund. He’s 63 next month.
It's all quite extraordinary really. I have to pinch myself at such a find. You once worried about the "sexiness" of what they have to offer, but for me, its the solidity, quality, vision and potential for growth that is most exciting. We can all latch onto the latest hype-driven trend and watch stocks rise, drop or even fall by the wayside, but IMO this is a company that will stay the distance and prosper and I think 78p in the nearish future is more than likely. Sex appeal works, business brains are better! (Been on the wine again!)
For awareness btw, there is a company called AbcDx that are trying to do exactly what Upfront are. They are being assisted by BBI (one of our major competitors), but seem to me to be AT LEAST 6 months behind Upfront.
https://www.abcdx.ch/solution/lvocheck
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1327348/full
TBH I think one advantage here is that unlike many other stocks, we’re not waiting on a single catalyst but instead have our fingers in so many pies. At the moment I’m watching out for any news on;
Septiloop sales/take up.
Salistick launch in new territories and possibly FDA authorisation. Equally any new U.K. retailers
Upfront funding and UKCA
Another own label Boots product(s)
News on EcoFlo pro type testing/results and possible commercial launch
And this is all just what’s on my radar for Q2/3, and ignores 52North, FOFH, and any other surprises we know nothing about.
I never put too much store in analyst predictions but 78p really doesn’t sound ridiculous to me as a 12 month target. If we were to do it though, the beauty is that it should be founded on solid year on year annuity income.
And as I’ve said before, our risk is spread widely across customers who have all spent years getting to where they are, and who therefore have every incentive to achieve commercial success.
This is the interesting drop before buys suddenly increase lol. Been waiting for this so I can buy my last batch. Win, win I say. I wonder who's buying in tomorrow?
I bet you're right, my last buy was listed as a sale....
Onwards and upwards Monk...
Wow Muck, that sounds like a huge catalyst for the raise in share price we are all expecting.Im really looking forward to the trading results for the rest of this year. The market can't ignore us for much longer.
Don't think so Ant - Everything at 10.34 is definitely a buy, and I suspect so are those at 10.12.
Only the trades at 10 dead are sells I think.